Prof Oliver Sartor

Professor Sartor is a medical oncologist and an internationally recognised expert in prostate cancer. He is the Laborde Professor for Cancer Research, Medical Director of the Tulane Cancer Center, and Assistant Dean for Oncology at Tulane University School of Medicine in New Orleans, Louisiana.

Professor Sartor is a past member of the Board of Scientific Counselors (Clinical Sciences and Epidemiology) at the National Cancer Institute and previously served as Chairman of the Prostate Cancer Integration Panel for the US Department of Defense. Professor Sartor has chaired five Data Monitoring Committees for Phase III trials that lead to FDA approval. He is medical oncology chair of the Genitourinary committee of NRG Oncology.

Professor Sartor received his Doctor of Medicine from Tulane University with honours in 1982. After his internship at the University of Pennsylvania, he trained in Internal Medicine at Tulane Medical School. After completing his fellowship at the National Cancer Institute in Bethesda, Maryland in 1989, he served until 1993 as a Senior Investigator at the National Cancer Institute with a focus on novel therapeutics for advanced prostate cancer patients.

Prof Andrei Iagaru

Dr Iagaru is a Professor of Radiology – Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University. His research focus includes PET/MRI and PET/CT imaging for early cancer detection as well as peptide-based diagnostic imaging and therapy. Dr Iagaru is also passionate about clinical translation of novel PET radiopharmaceuticals.

Since joining the faculty at Stanford in 2007, Dr Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; and the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM. Dr Iagaru published more than 200 papers in peer-reviewed journals, as well as 7 book chapters and 1 book.

Dr Neal Shore

Dr Shore MD, Medical Director of Carolina Urologic Research Centre. He has conducted more than 400 clinical trials with a particular focus on genitourinary (GU) oncology indications and is an internationally recognised expert and researcher in systemic therapies for patients with advanced urologic cancers, such as prostate, kidney and bladder cancers.

Dr Shore has more than 250 peer reviewed publications and numerous book chapters. He completed his general surgery/urology residence at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. Dr Shore serves on the SITC Guidelines Committee for Bladder Cancer as well as the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. Dr Shore is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and also serves as Editor, Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

Prof Jason Lewis

Professor Lewis is the Emily Tow Jackson Chair in Oncology and serves as Vice Chair for Research in the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK), Chief of MSK’s Radiochemistry & Imaging Sciences Service, and Director of MSK’s Radiochemistry and Molecular Imaging Probe Core Facility. He is head of a laboratory in the Sloan Kettering Institute’s Molecular Pharmacology Program and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill Cornell Medical College. He is an Adjunct Professor in the Department of Biomedical Imaging and Image Guided Therapy, The Medical University of Vienna, Austria.

Professor Lewis holds a PhD from The University of Kent (UK) and has published over 300 papers, books, book chapters, and reviews in the field of cancer imaging. He has served as the President of the World Molecular Imaging Society and was named a Fellow (FWMIS) in 2015. He has received the SNMMI Michael J. Welch award, the Paul C. Aebersold Award for Outstanding Achievement in Basic Science Applied to Nuclear Medicine, the Distinguished Investigator Award from the Academy of Radiology Research and the ACS Bioconjugate Chemistry Lectureship Award. He has been named a Fellow of the Society of Nuclear Medicine and Molecular Imaging (FSNMMI), a Fellow of the Royal Society of Chemistry (FRSC) and a Fellow of the American Association for the Advancement of Science (FAAAS). In 2019 Professor Lewis was awarded an NCI Outstanding Investigator Award (R35) to support his work in radiochemistry and molecular imaging.

Prof Paul Donnelly

Professor Donnelly is the Clarity Group leader of the Donnelly Research Group, The University of Melbourne, based in the state-of-art laboratories of the Bio21 Institute of Molecular Science and Biotechnology.

Professor Donnelly’s expertise is in the application of synthetic inorganic/organic chemistry in biology and materials science, with a particular focus on the application of coordination chemistry to metal based drugs and the study of metal ions in biological systems. Professor Donnelly has an impressive publication record and is the inventor of a number of novel and patented radiopharmaceutical technologies.

Prof Louise Emmett

Prof Emmett is the Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital Sydney, a conjoint professor of medicine at the University of New South Wales and clinical research leader at the Garvan Institute of Medical Research. Since joining the Nuclear Medicine and Positron Emission Tomography (PET) department at St Vincent’s Hospital in 2012, Prof Emmett has been instrumental in developing the theranostics initiative at the St Vincent’s Campus, introducing new radiopharmaceuticals for clinical and research evaluation of cancer as well as setting up radiopharmacy production of a number of imaging and therapy tracers.

Prof Emmett is heavily involved in multidisciplinary clinical development and cancer research, including both imaging and therapy. She is the principal investigator of a number of prospective randomised national trials in Australia, being a big believer in the power of clinical research to optimise treatments and improve patients’ lives. She is passionate about translational science, collaborating with biotechnology companies to bring promising theranostic agents into the clinic.

Prof Emmett completed medical school at Auckland University (1992), New Zealand prior to completing her specialty training in Nuclear Medicine in Sydney and receiving her Fellow of the Royal Australasian College of Physicians (FRACP) qualification in 1999. She undertook a specialty fellowship in Nuclear Cardiology at the University Health Network in Toronto, Canada in 2001, and completed a Doctorate of Medicine in Nuclear Cardiology through Auckland University in 2014. Prof Emmett is a clinical professor with the University of New South Wales with a strong interest in research. She has published over 100 original papers in peer reviewed journals in the last 10 years, has received a number of grants for clinical research and has presented at numerous national and international meetings.

Jon Stoner

Mr Stoner is the director of the Idaho Accelerator Center (IAC), a research institute of Idaho State University. He has been researching isotope production using linear accelerators for 14 years and pioneered a new process and mechanism for producing therapeutic copper-67 that enables it to be manufactured in the quantities and quality required for clinical development. He has 10 years of experience in production of the copper-67 isotope, and under his leadership the IAC has been shipping copper-67 commercially since 2014, supporting Clarity’s Targeted Copper Theranostic programs from preclinical through to the clinic where there are now three therapy products in clinical development.

Mr Stoner has 3 patents on production of copper-67 and has 11 related publications. He has worked in many technical and business roles in high technology for more than 34 years including Sr. VP and Chief Technology Officer of AMI Semiconductor where he was responsible for world-wide R&D and Intellectual Property, General Manager of the Image Sensor Business Unit and Founder and Managing Partner of C&J Tech Consulting – a company supplying technical evaluation support to Private Equity investors and other clients.